ImmunityBio, Inc. (IBRX)
11.30
-0.25
(-2.16%)
USD |
NASDAQ |
Feb 25, 10:32
ImmunityBio Research and Development Expense (Quarterly) : 63.36M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Novavax, Inc. | 98.17M |
| Krystal Biotech, Inc. | 13.23M |
| Rapt Therapeutics, Inc. | 12.03M |
| Moderna, Inc. | 708.00M |
| Corcept Therapeutics, Inc. | 68.85M |